| Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management |
91 |
| Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges |
45 |
| T cell acute lymphoblastic leukemia (T-ALL): New insights into the cellular origins and infiltration mechanisms common and unique among hematologic malignancies |
26 |
| Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: The dawn of a new era? |
21 |
| Blocking don't eat me signal of CD47-SIRP alpha in hematological malignancies, an in-depth review |
21 |
| Genotype-phenotype associations in Fanconi anemia: A literature review |
20 |
| A paradigm shift on beta-thalassaemia treatment: How will we manage this old disease with new therapies? |
18 |
| Cardiovascular, pulmonary, and metabolic toxicities complicating tyrosine kinase inhibitor therapy in chronic myeloid leukemia: Strategies for monitoring, detecting, and managing |
17 |
| When the good go bad: Mutant NPM1 in acute myeloid leukemia |
15 |
| CAR-T - and a side order of IgG, to go? - Immunoglobulin replacement in patients receiving CAR-T cell therapy |
14 |
| Apoptosis signaling and BCL-2 pathways provide opportunities for novel targeted therapeutic strategies in hematologic malignances |
14 |
| A storm in the niche: Iron, oxidative stress and haemopoiesis |
14 |
| Chronic lymphocytic leukemia and infection risk in the era of targeted therapies: Linking mechanisms with infections |
13 |
| Bispecific antibody based therapeutics: Strengths and challenges |
13 |
| Infections in patients with chronic lymphocytic leukaemia: Mitigating risk in the era of targeted therapies |
12 |
| Atrial fibrillation and cancer - An unexplored field in cardiovascular oncology |
12 |
| Factor VIII: Long-established role in haemophilia A and emerging evidence beyond haemostasis |
12 |
| Cellular therapy for acute myeloid Leukemia - Current status and future prospects |
12 |
| The emerging role of exosomes in multiple myeloma |
12 |
| Epidemiology of myelodysplastic syndromes: Why characterizing the beast is a prerequisite to taming it |
12 |
| Plasma contact factors as therapeutic targets |
12 |
| Challenges of blood transfusions in beta-thalassemia |
11 |
| The impact of NF-kappa B signaling on pathogenesis and current treatment strategies in multiple myeloma |
11 |
| Review of immune tolerance induction in hemophilia A |
11 |
| What can we learn from ineffective erythropoiesis in thalassemia? |
10 |
| Management of the aging beta-thalassemia transfusion-dependent population - The Italian experience |
10 |
| Everything the clinician needs to know about evidence-based anticoagulation in pregnancy |
10 |
| Allogeneic hematopoietic cell transplantation; the current renaissance |
9 |
| Iron toxicity - Its effect on the bone marrow |
9 |
| Time to repeal and replace response criteria for acute myeloid leukemia? |
9 |
| Prognostication of diffuse large B-cell lymphoma in the molecular era: moving beyond the IPI |
9 |
| Dueling for dual inhibition: Means to enhance effectiveness of PI3K/Akt/mTOR inhibitors in AML |
9 |
| Hypertension in hematologic malignancies and hematopoietic cell transplantation: An emerging issue with the introduction of novel treatments |
9 |
| The global problem of early deaths in acute promyelocytic leukemia: A strategy to decrease induction mortality in the most curable leukemia |
9 |
| Evolution of replacement therapy for von Willebrand disease: From plasma fraction to recombinant von Willebrand factor |
9 |
| Mechanisms of extramedullary relapse in acute lymphoblastic leukemia: Reconciling biological concepts and clinical issues |
8 |
| Current and evolving understanding of atypical chronic myeloid leukemia |
8 |
| Effect of the ABO blood group on susceptibility to severe malaria: A systematic review and meta-analysis |
8 |
| Clinical significance of altered collagen-receptor functioning in platelets with emphasis on glycoprotein VI |
8 |
| Prognostic and therapeutic role of CLEC12A in acute myeloid leukemia |
8 |
| T-cell acute lymphoblastic leukemia from miRNA perspective: Basic concepts, experimental approaches, and potential biomarkers |
7 |
| Myeloid-derived suppressor cells in lymphoma: The good, the bad and the ugly |
7 |
| To chelate or not to chelate in MDS: That is the question! |
7 |
| Setting the stage for individualized therapy in hemophilia: What role can pharmacokinetics play? |
7 |
| Acquired Glanzmann thrombasthenia: From antibodies to anti-platelet drugs |
7 |
| Extramedullary disease in multiple myeloma - controversies and future directions |
7 |
| Evolution of survivorship in lymphoma, myeloma and leukemia: Metamorphosis of the field into long term follow-up care |
7 |
| Targeting steroid resistance in T-cell acute lymphoblastic leukemia |
7 |
| Cellular immunotherapy for acute myeloid leukemia: How specific should it be? |
6 |
| Current status and trends in the diagnostics of AML and MDS |
6 |
